This biotech innovator in antibody therapies for inflammatory bowel disease reported a notable insider sale, according to a recent SEC filing.Spyre Therapeutics' CEO Sells 15,000 Shares for $460KThis biotech innovator in antibody therapies for inflammatory bowel disease reported a notable insider sale, according to a new SEC filing.Cameron Turtle, Chief Executive Officer of Spyre Therapeutics (SYRE +1.56%), directly sold 15,000 shares in open-market transactions on Jan. 2, for a total consideration of more ...